Skip to content
Eris Biotech logo

Eris Biotech

Eris Biotech is a YC Winter 2024 (W24) company. Based in Lehi, UT, USA. Team of 2.

  • Biotech
  • Therapeutics
  • Drug discovery
  • Oncology

About Eris Biotech

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Eris Biotech develops small-molecule drugs that block the pathway cancer cells use to hide from the immune system, allowing the immune system to attack tumors directly. Its lead asset is an orally administered, first-in-class inhibitor that does not target a protein, broadening the eligible patient population beyond what current biologics reach. The therapeutic portfolio focuses on solid tumors, beginning with mesothelioma, and replaces the need for protein-dependent immunotherapy approaches in those indications.

From the Y Combinator listing

How Eris Biotech describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Our drugs engage the immune system to fight tumors

We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
Lehi, UT, USA
Team size
2
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works